Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Mar;141(3):620-30.
doi: 10.1017/S0950268812001148. Epub 2012 Jun 13.

Age-specific vaccine effectiveness of seasonal 2010/2011 and pandemic influenza A(H1N1) 2009 vaccines in preventing influenza in the United Kingdom

R G Pebody  1 , N Andrews  1 , D M Fleming  2 , J McMenamin  3 , S Cottrell  4 , B Smyth  5 , H Durnall  2 , C Robertson  3 , W Carman  6 , J Ellis  7 , P Sebastian-Pillai  7 , M Zambon  7 , C Kearns  5 , C Moore  4 , D Rh Thomas  4 , J M Watson  1
Affiliations

Age-specific vaccine effectiveness of seasonal 2010/2011 and pandemic influenza A(H1N1) 2009 vaccines in preventing influenza in the United Kingdom

R G Pebody et al. Epidemiol Infect. 2013 Mar.

Abstract

An analysis was undertaken to measure age-specific vaccine effectiveness (VE) of 2010/11 trivalent seasonal influenza vaccine (TIV) and monovalent 2009 pandemic influenza vaccine (PIV) administered in 2009/2010. The test-negative case-control study design was employed based on patients consulting primary care. Overall TIV effectiveness, adjusted for age and month, against confirmed influenza A(H1N1)pdm 2009 infection was 56% (95% CI 42-66); age-specific adjusted VE was 87% (95% CI 45-97) in <5-year-olds and 84% (95% CI 27-97) in 5- to 14-year-olds. Adjusted VE for PIV was only 28% (95% CI -6 to 51) overall and 72% (95% CI 15-91) in <5-year-olds. For confirmed influenza B infection, TIV effectiveness was 57% (95% CI 42-68) and in 5- to 14-year-olds 75% (95% CI 32-91). TIV provided moderate protection against the main circulating strains in 2010/2011, with higher protection in children. PIV administered during the previous season provided residual protection after 1 year, particularly in the <5 years age group.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
Trivalent influenza vaccine effectiveness 2010/11 against (a) H1N1 (2009) and (b) flu B by age group UK, 2010–11.
Fig. 2.
Fig. 2.
Pandemic influenza vaccine 2009 effectiveness against H1N1 (2009) by age group UK, 2010–11.
Fig. 3.
Fig. 3.
Trivalent influenza vaccine effectiveness 2010/11 against (a) influenza H1N1 (2009) and (b) flu B by surveillance scheme, 2010/11, UK. RCGP, Royal College of General Practitioners' surveillance scheme; RMN, Health Protection Agency (HPA) Regional Microbiology Network; HPS, Health Protection Scotland.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Wichmann O, et al. Pandemic influenza A(H1N1) 2009 breakthrough infections and estimates of vaccine effectiveness in Germany 2009–2010. Eurosurveillance 2010; 15. - PubMed
    1. Valenciano M, et al. Estimates of pandemic influenza vaccine effectiveness in Europe, 2009–2010: results of influenza monitoring vaccine effectiveness in Europe (I-MOVE) multicentre case-control study. PLoS Medicine 2011; 8: e1000388. - PMC - PubMed
    1. Hardelid P, et al. Effectiveness of pandemic and seasonal influenza vaccine in preventing pandemic influenza A(H1N1)2009 infection in England and Scotland 2009–2010. Eurosurveillance 2011; 16. - PubMed
    1. Andrews N, et al. Age-specific effectiveness of an oil-in-water adjuvanted pandemic (H1N1) 2009 vaccine against confirmed infection in high risk groups in England. Journal of Infectious Diseases 2011; 203: 32–39. - PMC - PubMed
    1. Pebody R, et al. Effectiveness of seasonal 2010/11 and pandemic influenza A(H1N1)2009 vaccines in preventing influenza infection in the United Kingdom: mid-season analysis 2010/11. Eurosurveillance 2011; 16. - PubMed

Publication types

Substances